NCT01680549

Brief Summary

The purpose of this project is to study the effects of gabapentin on pain control in the perioperative and post-operative period of total knee arthroplasty.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at below P25 for phase_4 postoperative-pain

Timeline
Completed

Started Sep 2012

Longer than P75 for phase_4 postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

September 4, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 7, 2012

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

March 17, 2017

Completed
Last Updated

January 31, 2024

Status Verified

January 1, 2024

Enrollment Period

3.4 years

First QC Date

September 4, 2012

Results QC Date

November 28, 2016

Last Update Submit

January 9, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Patient Pain Scores

    Patient's pain assessed by the Visual Analog Scale (VAS - Units on a scale) on postoperative days 0, 1 and 2. Scale range: 0-100 Higher Values = More Pain

    3 days

Secondary Outcomes (3)

  • Narcotics Consumption

    3 days

  • Knee Range of Motion

    3 days

  • Patient Restfulness

    3 days

Study Arms (2)

Gabapentin

ACTIVE COMPARATOR

Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.

Drug: Gabapentin

Placebo

PLACEBO COMPARATOR

Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days

Drug: Gabapentin

Interventions

Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.

Also known as: Fanatrex, Gabarone, Gralise, Horizant, Neurontin
GabapentinPlacebo

Eligibility Criteria

Age25 Years - 89 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 25 years old
  • Primary osteoarthritis of the knee
  • Must be undergoing unilateral total knee arthroplasty
  • Anesthesia assesment score I, II, or III

You may not qualify if:

  • Severe joint malalignment (defined as varus/valgus angle \> 20 deg)
  • Use of gabapentin pre-operatively
  • History of chronic pain (currently under treatment)
  • History of substance abuse
  • Impaired kidney function (defined as creatinine \> 1.5)
  • Epilepsy (currently on medication for treatment)
  • Known allergy to Gabapentin
  • Known history of depression or suicidal thoughts and behaviors
  • Anyone who is not a candidate for general anesthesia or any other portion of the investigator's standard of care.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

TTUHSC Orthopaedic Surgery MS 9436

Lubbock, Texas, 79430, United States

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Gabapentin

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AminesOrganic Chemicalsgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAmino AcidsAmino Acids, Peptides, and Proteins

Results Point of Contact

Title
Nancy Swinford
Organization
Texas Tech University Health Sciences Center

Study Officials

  • George W Brindley, MD

    TTUHSC dept. Orthopaedic Surgery

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 4, 2012

First Posted

September 7, 2012

Study Start

September 1, 2012

Primary Completion

February 1, 2016

Study Completion

February 1, 2016

Last Updated

January 31, 2024

Results First Posted

March 17, 2017

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations